Varian, a Siemens Healthineers Company
Trial Pipeline
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT06681233
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT05764720
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
NCT05765175
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
NCT05197881
Evaluation of Improved Onboard Patient Imaging
NCT06187103
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System
NCT05975619
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax
NCT05524064
CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation
NCT02661048
What the Pipeline for Varian, a Siemens Healthineers Company Shows
According to the ClinicalTrials.gov registry, Varian, a Siemens Healthineers Company is linked to 9 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 56% of the sponsor's indexed portfolio — and 1 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Varian, a Siemens Healthineers Company reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Varian, a Siemens Healthineers Company is Pelvic Cancer with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.